- Companies
- Nxera Pharma
Nxera Pharma Valuation Multiples
Nxera Pharma is valued at $700M as of October 2026, a 3.8x revenue multiple. In the last 12 months, Nxera Pharma revenue was $245M and Nxera Pharma EBITDA was $45M.
Nxera Pharma Overview
About Nxera Pharma
Nxera Pharma is a biopharmaceutical company founded in 1990 and based in Japan. OPF1 is a fund launched in September 2023 with JIC VGI as its General Partner, whose strategy is to provide funding to direct secondary deals and listed startups. OPF1 is one ofthe JIC's initiatives included in the government's "Startup Development Five-Year Plan". The company serves business and institutional customers through products and services in the biopharmaceutical market. Its commercial model is built primarily on technology licensing and product sales, reflecting the way customers obtain and use its offering. JIC Venture Growth Investments classifies the business in its After Market portfolio and records December 2023 for the company. The company maintains its operating website at www.nxera.life, while JIC VGI's portfolio materials preserve the public record of the investment relationship.
Founded
1990
HQ
Employees
443
Website
Financials (LTM)
EV
$931M
Valuation Multiples
Start free trialNxera Pharma Financials
Nxera Pharma reported last 12-month revenue of $245M and EBITDA of $45M.
In the same LTM period, Nxera Pharma generated $45M in EBITDA and $4M in net income.
Revenue (LTM)
Nxera Pharma P&L
In the most recent fiscal year, Nxera Pharma reported revenue of $187M and EBITDA of ($26M).
Nxera Pharma is unprofitable as of last fiscal year, with gross margin of 72%, EBITDA margin of (14%), and net margin of (42%).
Financial data powered by Morningstar, Inc.
Nxera Pharma Stock Performance
Nxera Pharma has current market cap of $700M, and enterprise value of $931M.
Market Cap Evolution
Nxera Pharma's stock price is $7.66.
Nxera Pharma share price decreased by 3.5% in the last 30 days, and increased by 31.7% in the last year.
Nxera Pharma has an EPS (earnings per share) of $-0.87.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $931M | $700M | -3.5% | -3.5% | 38.4% | 31.7% | $-0.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNxera Pharma Valuation Multiples
Nxera Pharma trades at 3.8x EV/Revenue multiple, and 20.7x EV/EBITDA.
EV / Revenue (LTM)
Nxera Pharma Financial Valuation Multiples
As of October 10, 2026, Nxera Pharma has market cap of $700M and EV of $931M.
Nxera Pharma has a P/E ratio of 191.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nxera Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Nxera Pharma Margins & Growth Rates
Nxera Pharma grew revenue by 39% but EBITDA decreased by 358% in the last fiscal year.
In the most recent fiscal year, Nxera Pharma reported gross margin of 72%, EBITDA margin of (14%), and net margin of (42%).
Nxera Pharma Margins
Nxera Pharma Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Nxera Pharma Operational KPIs
Nxera Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Nxera Pharma's Rule of 40 is 65% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nxera Pharma's Rule of X is 123% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Nxera Pharma Competitors
Nxera Pharma competitors include 4D Molecular Therapeutics, SK Chemicals, Sanofi India, Olema Pharmaceuticals, WAVE Life Sciences, Gyre Therapeutics, Pharming, Supriya Lifescience, Design Therapeutics and Collegium Pharmaceutical.
Most Nxera Pharma public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $85M | ($152M) | 4.5x | 12.8x | (2.5x) | (1.4x) | |||
| $1.8B | $172M | 1.0x | 0.9x | 10.5x | 9.7x | |||
| $189M | $49M | 3.6x | 3.4x | 13.9x | 12.0x | |||
| - | ($178M) | - | - | (1.3x) | (1.0x) | |||
| $43M | ($196M) | 5.5x | 5.0x | (1.2x) | (1.1x) | |||
| $117M | $15M | 6.0x | 6.3x | 46.2x | (16.4x) | |||
| $376M | $34M | 1.7x | 1.7x | 19.0x | 23.7x | |||
| $83M | $31M | 8.6x | 7.5x | 23.0x | 21.6x | |||
This data is available for Pro users. Sign up to see all Nxera Pharma competitors and their valuation data. Start Free Trial | ||||||||
Nxera Pharma VC Funding History
Before going public, Nxera Pharma raised funding across 1 round.
Nxera Pharma Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nxera Pharma
| When was Nxera Pharma founded? | Nxera Pharma was founded in 1990. |
| Where is Nxera Pharma headquartered? | Nxera Pharma is headquartered in Japan. |
| How many employees does Nxera Pharma have? | As of today, Nxera Pharma has over 443 employees. |
| Who is the CEO of Nxera Pharma? | Nxera Pharma's CEO is Christopher Cargill. |
| Is Nxera Pharma publicly listed? | Yes, Nxera Pharma is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Nxera Pharma? | Nxera Pharma trades under 4565 ticker. |
| When did Nxera Pharma go public? | Nxera Pharma went public in 2004. |
| Who are competitors of Nxera Pharma? | Nxera Pharma main competitors include 4D Molecular Therapeutics, SK Chemicals, Sanofi India, Olema Pharmaceuticals, WAVE Life Sciences, Gyre Therapeutics, Pharming, Supriya Lifescience, Design Therapeutics, Collegium Pharmaceutical. |
| What is the current market cap of Nxera Pharma? | Nxera Pharma's current market cap is $700M. |
| What is the current revenue of Nxera Pharma? | Nxera Pharma's last 12 months revenue is $245M. |
| What is the current revenue growth of Nxera Pharma? | Nxera Pharma revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Nxera Pharma? | Current revenue multiple of Nxera Pharma is 3.8x. |
| What is the current EBITDA of Nxera Pharma? | Nxera Pharma's last 12 months EBITDA is $45M. |
| What is Nxera Pharma's EBITDA margin? | Nxera Pharma's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Nxera Pharma? | Current EBITDA multiple of Nxera Pharma is 20.7x. |
| How many companies Nxera Pharma has acquired to date? | Nxera Pharma hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Nxera Pharma has invested to date? | Nxera Pharma hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Nxera Pharma
Lists including Nxera Pharma
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




